Role of MHC and non-MHC alloantibodies in graft rejection

Current Opinion in Organ Transplantation

Volumn 9, Issue 1, 2004, Pages 16-22

  Rose, Marlene L ^a  

^a HAREFIELD HOSPITAL   (United Kingdom)

Author keywords

Alloantibodies; Endothelial cell antibodies; MHC antigens; Non HLA alloantibodies

Indexed keywords

EID: 14344257009     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/00075200-200403000-00005     Document Type: Review

References (50)

1. Baier KA, Meyer JA, O'Brien BJ, et al.: Solubilized HLA class I antigen enzyme-linked immunoassay to identify HLA-typing reagents. Hum Immunol 1994, 40:187-190.
2. Kao KJ, Scornik JC, Small SJ: Enzyme-linked immunoassay for anti-HLA antibodies-an alternative to panel studies by lymphocytotoxicity. Transplantation 1993, 55:192-196.
3. Pei R, Wang G, Tarsitani C, et al.: Simultaneous HLA class I and class II antibodies screening with flow cytometry. Hum Immunol 1998, 59:313-322.
4. Itescu S, Tung TC, Burke EM, et al.: Preformed IgG antibodies against major histocompatibility complex class II antigens are major risk factors for highgrade cellular rejection in recipients of heart transplantation. Circulation 1998, 98:786-793.
5. Smith JD, Danskine AJ, Laylor RM, et al.: The effect of panel reactive antibodies and the donor specific crossmatch on graft survival after heart and heartlung transplantation. Transpl Immunol 1993, 1:60-65.
6. Page C, Rose M, Yacoub M, et al.: Antigenic heterogeneity of vascular endothelium. Am J Pathol 1992, 141:673-683.
7. Palmer SM, Davis RD, Hadjiliadis D, et al.: Development of an antibody specific to major histocompatibility antigens detectable by flow cytometry afterlung transplant is associated with bronchiolitis obliterans syndrome. Transplantation 2002, 74:799-804.
8. Jaramillo A, Smith MA, Phelan D, et al.: Development of ELISA-detected anti- HLA antibodies precedes the development of bronchiolitis obliterans syndrome and correlates with progressive decline in pulmonary function after lung transplantation. Transplantation 1999, 67:1155-1161.
9. Worthington JE, Martin S, Al Husseini DM, et al.: Posttransplantation production of donor HLA-specific antibodies as a predictor of renal transplant outcome. Transplantation 2003, 75:1034-1040.
10. Bas-Bernardet S, Hourmant M, Valentin N, et al.: Identification of the antibodies involved in B-cell crossmatch positivity in renal transplantation. Transplantation 2003, 75:477-482.
11. Cerilli J, Bay W, Brasile L: The significance of the monocyte crossmatch in recipients of living-related HLA identical kidney grafts. Hum Immunol 1983, 7:45-50.
12. Moraes JR, Stastny P: Human endothelial cell antigens: molecular independence from HLA and expression in blood monocytes. Transplant Proc 1977, 9:605-607.
13. Perrey C, Brenchley PE, Johnson RW, et al.: An association between antibodies specific for endothelial cells and renal transplant failure. Transpl Immunol 1998, 6:101-106.
14. Sumitran-Karuppan S, Tyden G, Reinholt F, et al.: Hyperacute rejections of two consecutive renal allografts and early loss of the third transplant caused by non-HLA antibodies specific for endothelial cells. Transpl Immunol 1997, 5:321-327.
15. Dunn MJ, Crisp SJ, Rose ML, et al.: Anti-endothelial antibodies and coronary artery disease after cardiac transplantation. Lancet 1992, 339:1566-1570.
16. Ferry BL, Welsh KI, Dunn MJ, et al.: Anti-cell surface endothelial antibodies in sera from cardiac and kidney transplant recipients: association with chronic rejection. Transpl Immunol 1997, 5:17-24.
17. Faulk WP, Rose M, Meroni PL, et al.: Antibodies to endothelial cells identify myocardial damage and predict development of coronary artery disease in patients with transplanted hearts. Hum Immunol 1999, 60:826-832.
18. Fredrich R, Toyoda M, Czer LS, et al.: The clinical significance of antibodies to human vascular endothelial cells after cardiac transplantation. Transplantation 1999, 67:385-391.
19. Magro CM, Deng A, Pope-Harman A, et al.: Humorally mediated posttransplantation septal capillary injury syndrome as a common form of pulmonary allograft rejection: a hypothesis. Transplantation 2002, 74:1273-1280.
20. Bas-Bernardet S, Hourmant M, Coupel S, et al.: Non-HLA-type endothelial cell reactive alloantibodies in pre-transplant sera of kidney recipients trigger apoptosis. Am J Transplant 2003, 3:167-177.
21. Jaramillo A, Naziruddin B, Zhang L, et al.: Activation of human airway epithelial cells by non-HLA antibodies developed after lung transplantation: a potential etiological factor for bronchiolitis obliterans syndrome. Transplantation 2001, 71:966-976.
22. Wheeler CH, Collins A, Dunn MJ, et al.: Characterization of endothelial antigens associated with transplant-associated coronary artery disease. J Heart Lung Transplant 1995, 14:S188-S197.
23. Danskine AJ, Smith JD, Stanford RE, et al.: Correlation of anti-vimentin antibodies with acute and chronic rejection following cardiac transplantation. Hum Immunol 2002, 63:S30-S31.
24. Jurcevic S, Ainsworth ME, Pomerance A, et al.: Antivimentin antibodies are an independent predictor of transplant-associated coronary artery disease after cardiac transplantation. Transplantation 2001, 71:886-892.
25. Miller LW, Granville DJ, Narula J, et al.: Apoptosis in cardiac ransplant rejection. Cardiol Clin 2001, 19:141-154.
26. Propato A, Cutrona G, Francavilla V, et al.: Apoptotic cells overexpress vinculin and induce vinculin-specific cytotoxic T-cell cross-priming. Nat Med 2001, 7:807-813.
27. Barber LD, Whitelegg A, Madrigol JA, et al.: Detection of vimentin specific autoreactive CD8+ T cells in cardiac transplant patients. Transplantation 2004, in press.
28. Fedoseyeva EV, Tam RC, Popov IA, et al.: Induction of T cell responses to aself-antigen following allotransplantation. Transplantation 1996, 61:679-683.
29. Dunn MJ, Rose ML, Latif N, et al.: Demonstration by Western blotting of antiheart antibodies before and after cardiac transplantation. Transplantation 1991, 51:806-812.
30. Warraich RS, Pomerance A, Stanley A, et al.: Cardiac myosin autoantibodies and acute rejection after heart transplantation in patients with dilated cardiomyopathy. Transplantation 2000, 69:1609-1617.
31. Laguens RP, Argel MI, Chambo JG, et al.: Anti-skeletal muscle glycolipid antibodies in human heart transplantation as markers of acute rejection. Correlation with endomyocardial biopsy. Transplantation 1996, 62:211-216.
32. Fang JC, Kinlay S, Behrendt D, et al.: Circulating autoantibodies to oxidized LDL correlate with impaired coronary endothelial function after cardiac transplantation. Arterioscler Thromb Vasc Biol 2002, 22:2044-2048
33. Haque MA, Mizobuchi T, Yasufuku K, et al.: Evidence for immune responses to a self-antigen in lung transplantation: role of type V collagen-specific T cells in the pathogenesis of lung allograft rejection. J Immunol 2002, 169:1542-1549.
34. Yasufuku K, Heidler KM, Woods KA, et al.: Prevention of bronchiolitis obliterans in rat lung allografts by type V collagen-induced oral tolerance. Transplantation 2002, 73:500-505.
35. Bates RL, Frampton G, Rose ML, Murphy JJ: High diversity of non-human leukocyte antigens in transplant-associated coronary artery disease. Transplantation 2003, 75:1347-1350.
36. Linke AT, Marchant B, Marsh P, et al.: Screening of a HUVEC cDNA library with transplant-associated coronary artery disease sera identifies RPL7 as a candidate autoantigen associated with this disease. Clin Exp Immunol 2001, 126:173-179.
37. Rosen A, Casciola-Rosen LA: Autoantigen as substrates for apoptotic proteases: implications for the pathogenesis of systemic autoimmune diseases. Cell Death Diff 1999, 6:6-12.
38. Casciola-Rosen LA, Anhalt G, Rosen A: Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J Exp Med 1994, 179:1317-1330.
39. Mevorach D, Zhou JL, Song X, et al.: Systemic exposure to irradiated apoptotic cells induces autoantibody production. J Exp Med 1998, 188:387-392.
40. Baker RJ, Hernandez-Fuentes MP, Brookes PA, et al.: Loss of direct and maintenance of indirect alloresponses in renal allograft recipients: implications for the pathogenesis of chronic allograft nephropathy. J Immunol 2001, 167:7199-7206.
41. Sumitran-Holgersson S, Wilczek HE, Holgersson J, et al.: Identification of the nonclassical HLA molecules, mica, as targets for humoral immunity associated with irreversible rejection of kidney allografts. Transplantation 2002, 74:268-277.
42. Bahram S: MIC genes: from genetics to biology. Adv Immunol 2000, 76:1-60.
43. Zwirner NW, Fernandez-Vina MA, Stastny P: MICA, a new polymorphic HLArelated antigen, is expressed mainly by keratinocytes, endothelial cells, and monocytes. Immunogenetics 1998, 47:139-148.
44. Brasile L, Zerbe T, Rabin B, et al.: Identification of the antibody to vascular endothelial cells in patients undergoing cardiac transplantation. Transplantation 1985, 40:672-675.
45. Meguro M, Nishimura F, Ohyama H, et al.: Ligation of IFN-[gamma]-induced HLA-DR molecules on fibroblasts induces RANTES expression via c-Jun Nterminal kinase (JNK) pathway. Cytokine 2003, 22:107-115.
46. Podor TJ, Singh D, Chindemi P, et al.: Vimentin exposed on activated platelets and platelet microparticles localizes vitronectin and plasminogen activator inhibitor complexes on their surface. J Biol Chem 2002, 277:7529-7539.
47. Grunebaum E, Blank M, Cohen S, et al.: The role of anti-endothelial cell antibodies in Kawasaki disease-in vitro and in vivo studies. Clin Exp Immunol 2002, 130:233-240.
48. Diujvestijn AM, Derhaag JG, Breda Vriesman PJ: Complement activation by anti-endothelial cell antibodies in MHC-mismatched and MHC-matched heart allograft rejection: anti-MHC-, but not anti non-MHC alloantibodies are effective in complement activation. Transpl Int 2000, 13:363-371.
49. Wu GD, Jin YS, Salazar R, et al.: Vascular endothelial cell apoptosis induced by anti-donor non-MHC antibodies: a possible injury pathway contributing to chronic allograft rejection. J Heart Lung Transplant 2002, 21:1174-1187.
50. Xu H, Yin D, Naziruddin B, et al.: The in vitro and in vivo effects of antigalactoseantibodies on endothelial cell activation and xenograft rejection. J Immunol 2003, 170:1531-1539.